---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-009696"
form_type: "8-K"
ticker: "QURE"
cik: "0001590560"
company_name: "uniQure N.V."
filed_at: "2024-07-09T23:59:59+00:00"
generated_at: "2026-05-31T22:35:42.235063+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# uniQure announces positive interim Phase I/II data for AMT-130: 80% slowing of Huntington's progression at high dose

## Summary
- High-dose AMT-130 showed 80% slowing of cUHDRS decline vs. external control at 24 months (p=0.007).
- CSF neurofilament light chain reduced 11% from baseline at 24 months in treated patients (p=0.02).
- AMT-130 received first-ever RMAT designation for Huntington's disease from FDA.
- Company expects to meet with FDA in H2 2024 to discuss expedited development and accelerated approval.
- No new AMT-130-related serious adverse events; safety profile manageable at both doses.

## SEC filing metadata
- accession: 0001558370-24-009696
- form_type: 8-K
- ticker: QURE
- cik: 0001590560
- company_name: uniQure N.V.
- filed_at: 2024-07-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1590560/000155837024009696/0001558370-24-009696-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1590560/000155837024009696/qure-20240709x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-009696
- JSON: https://secwatch.observer/filing/0001558370-24-009696.json
- Plain text: https://secwatch.observer/filing/0001558370-24-009696.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.